Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: A potential autocrine loop

European Journal of Endocrinology

Volumn 153, Issue 5, 2005, Pages 701-709

  Vieira, Joaquim Miguel ^a   Rosa Santos, Susana C ^a   Espadinha, Carla ^a   Correia, Isabel ^a   Vag, Tibor ^a   Casalou, Cristina ^a   Cavaco, Branca Maria ^a   Catarino, Ana Luísa ^a   Dias, Sérgio ^a   Leite, Valeriano ^a,b  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER CLASSIFICATION; CARCINOGENESIS; CELL VIABILITY; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL LINE; CELL SURVIVAL; GENETIC SCREENING; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27944499811     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02009     Document Type: Article

References (24)

1. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T & Shibuya M. Flt1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001 97 785-791.
2. Selheim F, Holmsen H & Vassbotn F. Identification of functional VEGF receptors on human platelets. FEBS Letters 2002 512 107-110.
3. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA & Rafii S. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. Journal of Clinical Investigation 2000 106 511-521.
4. von Marschall Z, Cramer T, Höcker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B & Rosewicz S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000 119 1358-1372.
5. Jackson M, Roberts J, Heckford S, Ricciardelli C, Stahl J, Horsfall D & Tilley W. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Research 2002 62 854-859.
6. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, Fusco A & Persico MG. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumours and cell lines. Oncogene 1995 11 1569-1579.
7. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA & Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumours and correlation with clinical pathological features. American Journal of Pathology 1999 155 1967-1976.
8. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A & Leclere J. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. Endocrinology 1999 161 41-49.
9. Fenton C, Patel A, Dinauer C, Robie D, Tuttle M & Francis G. The expression of vascular endothelial growth and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000 10 349-357.
10. Huang SM, Lee JC, Wu TJ & Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World Journal of Surgery 2001 25 302-306.
11. Arbiser J. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Seminars in Cancer Biology 2004 14 81-91.
12. Soares P, Trovisco V, Rocha A, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simones M. BRAF mutations and RET/PTC rearrangements are alternative events in the ethio-pathogenesis of PTC. Oncogene 2003 22 4578-4580.
13. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003 22 6455-6457.
14. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S. Clinical implications of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 2003 88 4393-4397.
15. Kim KH, Kang DW, Kim SH, Seong IO & Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Medical Journal 2004 45 818-821.
16. Xing M. BRAF mutation in thyroid cancer. Endocrine-related Cancer 2005 12 245-262.
17. DeGroot L, Kaplan E, McCormick M & Straus F. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424.
18. Hay I, Bergstralh E, Goellner J, Ebersold J & Grant C. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993 114 1050-1057.
19. Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. American Journal of Pathology 1995 147 9-19.
20. Tanaka K, Sonoo H, Kurebayashi J, Nomura T, Ohkubo S, Yamamoto Y & Yamamoto S. Inhibition of infiltration and angiogenesis by thrombospondin1 in papillary thyroid carcinoma. Clinical Cancer Research 2002 8 1125-1131.
21. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E & Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004 145 1031-1038.
22. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody Bevacizumab with chemotherapy in advanced colorectal cancer. Clinical Colorectal Cancer 2004 4 S62-S68.
23. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinase. Cancer Research 2002 62 7284-7290.
24. Kranenburg O, Gebbink M & Voest E. Stimulation of angiogenesis by Ras proteins. Biochimica et Biophysica Acta Reviews on Cancer 2004 1654 23-37.